Biosimilar Antibodies

Mocertatug Biosimilar – Research Grade, ProteoGenix, PX-TA2498-100

Modotuximab Biosimilar – Research Grade mAb, ProteoGenix, PX-TA1305-

Monalizumab Biosimilar – Anti-KLRC1, NKG2A, CD159a, CD94 mAb – Research Grade, ProteoGenix, PX-TA1392

Description of Monalizumab Biosimilar - Anti-KLRC1, NKG2A, CD159a, CD94 mAb - Research Grade General information on Anti-KLRC1/NKG2A/CD159a/CD94[Homo sapiens] (Monalizumab) Monoclonal Antibody Monalizumab has been investigated for the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.

Moponetug Biosimilar – Research Grade, ProteoGenix, PX-TA2499-100

Mosunetuzumab Biosimilar – Anti-CD3E, MS4A1, CD20 mAb – Research Grade, ProteoGenix, PX-TA1482

Description of Mosunetuzumab Biosimilar - Anti-CD3E, MS4A1, CD20 mAb - Research Grade The Structure of Mosunetuzumab Biosimilar Mosunetuzumab Biosimilar is a monoclonal antibody (mAb) that specifically targets three proteins – CD3E, MS4A1, and CD20. It is a biosimilar version of the original Mosunetuzumab, which was developed by Genentech and is currently in clinical trials for the treatment of non-Hodgkin’s lymphoma. The biosimilar version is being developed by a different pharmaceutical company and is intended for research purposes only. The structure of Mosunetuzumab Biosimilar is similar to that of the original Mosunetuzumab, with a few minor differences. It is a humanized IgG1 antibody, meaning that it is derived from human antibodies and has been modified to reduce immunogenicity. It consists of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to the target proteins, while the constant region is responsible for effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The Activity of Mosunetuzumab Biosimilar Mosunetuzumab Biosimilar is a bispecific antibody, meaning that it can bind to two different proteins at the same time. It binds to CD3E on T cells and MS4A1 on B cells, bringing these two cell types into close proximity. This leads to the activation of T cells, which then release cytokines and other molecules that help to kill the targeted B cells. In addition, Mosunetuzumab Biosimilar also binds to CD20 on B cells, triggering their death through ADCC and CDC. The ability of Mosunetuzumab Biosimilar to target multiple proteins and activate different immune mechanisms makes it a promising therapeutic option for the treatment of various B cell malignancies. It has shown particularly promising results in the treatment of non-Hodgkin’s lymphoma, where it has demonstrated high response rates in clinical trials. The Application of Mosunetuzumab Biosimilar Mosunetuzumab Biosimilar is currently being developed for research purposes only and is not yet approved for clinical use. However, it has the potential to be used as a therapeutic agent for the treatment of various B cell malignancies, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and multiple myeloma. In addition to its potential as a monotherapy, Mosunetuzumab Biosimilar also has the potential to be used in combination with other therapies, such as chemotherapy or other targeted therapies. Its bispecific nature and ability to activate different immune mechanisms make it a promising candidate for combination therapy, as it can potentially enhance the efficacy of other treatments. Overall, Mosunetuzumab Biosimilar has shown great promise as a potential therapeutic option for the treatment of B cell malignancies. Its unique structure, targeting multiple proteins, and ability to activate different immune mechanisms make it a versatile and potentially effective treatment option. Further research and clinical trials will be needed to fully understand its potential and determine its safety and efficacy in treating these diseases.

Muromonab-Cd3 Biosimilar – Research Grade mAb, ProteoGenix, PX-TA1092-

Nadecnemab Biosimilar – Anti-GFRA3 mAb – Research Grade, ProteoGenix, PX-TA1689

Description of Nadecnemab Biosimilar - Anti-GFRA3 mAb - Research Grade Introduction Nadecnemab Biosimilar, also known as Anti-GFRA3 mAb, is a research grade antibody that has shown promising results in the treatment of various diseases. In this article, we will discuss the structure, activity, and potential applications of this biosimilar in the field of medicine. Structure of Nadecnemab Biosimilar Nadecnemab Biosimilar is a monoclonal antibody (mAb) that is designed to target the GFRA3 protein. It is a recombinant antibody, meaning it is produced in a laboratory using genetic engineering techniques. The antibody is made up of two heavy chains and two light chains, which are connected by disulfide bonds. The heavy chains are responsible for the binding of the antibody to the target protein, while the light chains provide stability to the overall structure. The antibody also contains a constant region, which is responsible for the effector functions of the antibody, and a variable region, which is responsible for the specificity of the antibody towards its target. The variable region of Nadecnemab Biosimilar is designed to bind specifically to the GFRA3 protein, making it a highly targeted therapeutic agent. Activity of Nadecnemab Biosimilar The main activity of Nadecnemab Biosimilar is the inhibition of the GFRA3 protein. This protein is a co-receptor for the GDNF family ligands, which play a crucial role in the development and survival of various neuronal cells. In certain diseases, such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS), the GFRA3 protein is overexpressed, leading to excessive signaling and cell death. By binding to the GFRA3 protein, Nadecnemab Biosimilar blocks the interaction between the protein and its ligands, thereby inhibiting the downstream signaling pathways. This leads to a decrease in cell death and can potentially slow down the progression of these diseases. Potential Applications of Nadecnemab Biosimilar Nadecnemab Biosimilar has shown promising results in preclinical studies for the treatment of various diseases, including Parkinson’s disease, ALS, and multiple system atrophy (MSA). It has also been studied as a potential therapy for certain types of cancer, such as lung cancer and glioblastoma. In addition to its potential therapeutic applications, Nadecnemab Biosimilar can also be used as a research tool for studying the role of GFRA3 in different diseases. It can help researchers better understand the mechanisms of these diseases and develop new treatments. Parkinson’s Disease In Parkinson’s disease, the GFRA3 protein is overexpressed in the brain, leading to the degeneration of dopaminergic neurons. Studies have shown that Nadecnemab Biosimilar can effectively inhibit the GFRA3 protein and protect these neurons from cell death. This makes it a potential therapy for slowing down the progression of Parkinson’s disease. Amyotrophic Lateral Sclerosis (ALS) In ALS, the GFRA3 protein is overexpressed in the motor neurons, leading to their degeneration. Nadecnemab Biosimilar has been shown to protect these neurons from cell death, potentially slowing down the progression of the disease. It has also been found to improve motor function in animal models of ALS. Multiple System Atrophy (MSA) MSA is a rare neurodegenerative disease that affects the autonomic nervous system. Studies have shown that Nadecnemab Biosimilar can protect the neurons in this system from cell death, making it a potential therapy for MSA. Cancer Nadecnemab Biosimilar has also shown promising results in preclinical studies for the treatment of certain types of cancer. It has been found to inhibit the growth and metastasis of lung cancer and glioblastoma cells, making it a

Namilumab Biosimilar – Anti-CSF2, GM-CSF mAb – Research Grade, ProteoGenix, PX-TA1259

Description of Namilumab Biosimilar - Anti-CSF2, GM-CSF mAb - Research Grade General information on Anti-CSF2/GM-CSF[Homo sapiens] (Namilumab) Monoclonal Antibody Namilumab has beeninvestigated for the treatment of Plaque Psoriasis and Rheumatoid Arthritis.

Naptumomab Biosimilar – Anti-TPBG mAb – Research Grade, ProteoGenix, PX-TA1868

Description of Naptumomab Biosimilar - Anti-TPBG mAb - Research Grade Introduction to Naptumomab Biosimilar – Anti-TPBG mAb – Research Grade Naptumomab Biosimilar is a monoclonal antibody (mAb) that specifically targets the tumor-associated antigen TPBG (trophoblast glycoprotein). This biosimilar is a research grade version of the original Naptumomab, which is currently undergoing clinical trials for the treatment of various types of cancer. In this article, we will explore the structure, activity, and potential applications of Naptumomab Biosimilar in the field of cancer research. Structure of Naptumomab Biosimilar Naptumomab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, meaning it is derived from human antibodies and has been modified to reduce immunogenicity. It is composed of two identical heavy chains and two identical light chains, each containing a variable region and a constant region. The variable region is responsible for binding to the TPBG antigen, while the constant region is responsible for activating the immune system. The amino acid sequence of Naptumomab Biosimilar has been carefully engineered to mimic the structure of the original Naptumomab, ensuring high specificity and affinity for TPBG. This biosimilar has also been extensively characterized to ensure batch-to-batch consistency and stability. Activity of Naptumomab Biosimilar Naptumomab Biosimilar exerts its activity by binding to TPBG, a cell surface glycoprotein that is overexpressed in various types of cancer cells. This binding leads to the activation of the immune system, specifically the complement system and natural killer cells, which then target and destroy the cancer cells. In addition, Naptumomab Biosimilar also has the ability to induce antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). This means that the antibody can recruit immune cells to directly kill cancer cells or engulf them for destruction. Furthermore, Naptumomab Biosimilar has been shown to have a longer half-life compared to other anti-TPBG antibodies, allowing for sustained activity and potentially reducing the frequency of dosing. Potential Applications of Naptumomab Biosimilar The primary application of Naptumomab Biosimilar is in the treatment of cancer. As TPBG is highly expressed in various types of cancer, this biosimilar has the potential to be effective against a wide range of malignancies. Clinical trials of the original Naptumomab have shown promising results in the treatment of ovarian, lung, and pancreatic cancers. In addition, Naptumomab Biosimilar can also be used as a research tool in the study of TPBG and its role in cancer development and progression. It can also be used to investigate the potential of targeting TPBG as a therapeutic strategy in other diseases. Conclusion Naptumomab Biosimilar is a promising monoclonal antibody that specifically targets the tumor-associated antigen TPBG. Its carefully engineered structure and potent activity make it a valuable tool in cancer research and a potential therapeutic option for various types of cancer. As it undergoes further clinical trials, Naptumomab Biosimilar has the potential to improve the treatment options for cancer patients and contribute to the understanding of TPBG in cancer biology. Keywords: antibody, therapeutic target, Naptumomab Biosimilar, TPBG, monoclonal antibody, cancer, research grade

Naptumomab Estafenatox Biosimilar – Anti-TPBG mAb – Research Grade, ProteoGenix, PX-TA1050

Description of Naptumomab Estafenatox Biosimilar - Anti-TPBG mAb - Research Grade Naptumomab Estafenatox Biosimilar: A Promising Antibody for Targeting TPBG Introduction Naptumomab Estafenatox Biosimilar, also known as Anti-TPBG mAb, is a monoclonal antibody (mAb) that has shown great potential in targeting TPBG (trophoblast glycoprotein) for therapeutic purposes. This biosimilar is a research grade version of the original drug, which has been approved for clinical use in certain countries. In this article, we will explore the structure, activity, and potential applications of Naptumomab Estafenatox Biosimilar in more detail. Structure of Naptumomab Estafenatox Biosimilar Naptumomab Estafenatox Biosimilar is a recombinant humanized IgG1 mAb, meaning it is made from human and non-human components. It is produced through genetic engineering techniques, where the gene for the antibody is inserted into a host cell, such as Chinese hamster ovary (CHO) cells, to produce large quantities of the antibody. The resulting mAb has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains, connected by disulfide bonds. Activity of Naptumomab Estafenatox Biosimilar The main target of Naptumomab Estafenatox Biosimilar is TPBG, a glycoprotein that is overexpressed in various types of cancer, including breast, lung, and ovarian cancer. TPBG plays a role in promoting tumor growth and metastasis, making it a promising therapeutic target. Naptumomab Estafenatox Biosimilar binds to TPBG with high specificity and affinity, inhibiting its function and leading to tumor cell death. In addition to its direct anti-tumor activity, Naptumomab Estafenatox Biosimilar also has the ability to activate the immune system. It binds to Fc gamma receptors on immune cells, such as natural killer (NK) cells and macrophages, triggering an immune response against TPBG-expressing tumor cells. This mechanism, known as antibody-dependent cell-mediated cytotoxicity (ADCC), enhances the effectiveness of the antibody in killing cancer cells. Potential Applications Naptumomab Estafenatox Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer. Its potential applications include: 1. Targeted therapy for TPBG-expressing tumors As mentioned earlier, Naptumomab Estafenatox Biosimilar specifically targets TPBG, making it a potential therapy for cancers that overexpress this protein. It has shown efficacy in inhibiting tumor growth and inducing tumor cell death in preclinical studies, and is currently being evaluated in clinical trials for breast, lung, and ovarian cancer. 2. Combination therapy with other anti- cancer drugs Naptumomab Estafenatox Biosimilar has also been studied in combination with other anti- cancer drugs, such as chemotherapy and targeted therapy. These studies have shown that the antibody can enhance the effectiveness of these drugs, potentially leading to better treatment outcomes. 3. Immunotherapy for TPBG-negative tumors Although Naptumomab Estafenatox Biosimilar specifically targets TPBG, it has also shown some activity against TPBG-negative tumors. This is due to its ability to activate the immune system through ADCC. Therefore, it may have potential as an immunotherapy for a wider range of cancers. 4. Diagnostic tool for TPBG expression In addition to its therapeutic potential, Naptumomab Estafenatox Biosimilar can also be used as a diagnostic tool for TPBG expression. It can be labeled with a radioactive or fluorescent dye and used in imaging techniques, such as positron emission tomography (PET) or fluorescence microscopy, to detect TPBG-express